TRPM8-Rap1A Interaction Sites as Critical Determinants for Adhesion and Migration of Prostate and other Epithelial Cancer Cells

• Main Authors: Audero, M. (Author), Bailleul, Q. (Author), Bernardini, M. (Author), Bokhobza, A. (Author), Brysbaert, G. (Author), Cantelmo, A.R (Author), Chinigò, G. (Author), Cicero, J. (Author), De Ruyck, J. (Author), Gkika, D. (Author), Grolez, G.P (Author), Lensink, M.F (Author), Pla, A.F (Author), Ruffinatti, F.A (Author), Toillon, R.-A (Author), Visentin, L. (Author)
• Format: Article
• Language: English
• Published: MDPI 2022
• Subjects: adhesion; calcium channel; GTPase; metastasis; migration; prostate cancer; Rap1A; TRPM8
• Online Access: View Fulltext in Publisher
• ISBN: 20726694 (ISSN)
• DOI: 10.3390/cancers14092261

Emerging evidence indicates that the TRPM8 channel plays an important role in prostate cancer (PCa) progression, by impairing the motility of these cancer cells. Here, we reveal a novel facet of PCa motility control via direct protein-protein interaction (PPI) of the channel with the small GTPase Rap1A. The functional interaction of the two proteins was assessed by active Rap1 pull-down assays and live-cell imaging experiments. Molecular modeling analysis allowed the identification of four putative residues involved in TRPM8-Rap1A interaction. Point mutations of these sites impaired PPI as shown by GST-pull-down, co-immunoprecipitation, and PLA experiments and revealed their key functional role in the adhesion and migration of PC3 prostate cancer cells. More precisely, TRPM8 inhibits cell migration and adhesion by trapping Rap1A in its GDP-bound inactive form, thus preventing its activation at the plasma membrane. In particular, residues E207 and Y240 in the sequence of TRPM8 and Y32 in that of Rap1A are critical for the interaction between the two proteins not only in PC3 cells but also in cervical (HeLa) and breast (MCF-7) cancer cells. This study deepens our knowledge of the mechanism through which TRPM8 would exert a protective role in cancer progression and provides new insights into the possible use of TRPM8 as a new therapeutic target in cancer treatment. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.